M. Noman1, M. Ferrante1, R. Bisschops1, G. De Hertogh2, K. van den Broeck1, K. Rans1, P. Rutgeerts1, S. Vermeire1, G. van Assche1
1UZ Leuven, Gastroenterology, Leuven, Belgium, 2UZ Leuven, Campus Gasthuisberg, Pathology, Leuven, Belgium
Results: Of 118 initially recruited patients in the GEMINI LTS study, 68 patients (29 CD/39 UC) received vedolizumab beyond 1 year. Median treatment duration was 38 (range 13–73) months. Endoscopy data were available for 23 CD and 34 UC patients. At the last colonoscopy, 70% of UC patients maintained mucosal healing. In CD, 44% had complete and 38% had partial healing. In a total of 32 (CD) and 50 (UC) colonoscopies throughout the study and performed after a median of 2.7 years, Mayo score 0 (UC) and complete healing (CD) was observed in 54% and 44%, respectively. Low-grade dysplasia (LGD) was detected in 10% of patients. No high-grade dysplasia (HGD) or colorectal cancer was found in biopsies or resected lesions, although HGD was found in the colectomy specimen of a refractory patient with LGD in biopsies.
Conclusion: Long-term endoscopic healing is observed in a selected group of CD and UC patients treated with vedolizumab. Although even larger cohorts are needed, no new colonic dysplasia signal was found in this study.